関連する実験動画
Updated: Feb 13, 2026

03:57
Electrochemotherapy of Tumours
Published on: December 15, 2008
25.1K
腫瘍ネクロシス因子アンタゴニストが嗅覚に与える影響を調査
Andreas Espehana1,2, George Macfarlane1, Elizabeth Mairenn Garden1
1Norwich Medical School, University of East Anglia, Norwich, UK.
まとめ
腫瘍死滅因子 (TNF) アンタゴニストは,嗅覚機能障害のある個体において嗅覚機能を改善する可能性があります. これらの有望な発見を確認するために,この患者グループについてはさらなる研究が推奨されます.
科学分野:
- 免疫学 免疫学とは
- 神経学 神経学とは
- 耳鼻喉科 (Otorhinolaryngology) は,耳鼻喉科 (Otorhinolaryngology) を専門とする医療機関である.
背景:
- 腫瘍死滅因子 (TNF) アナゴニストは,抗炎症薬である.
- ネズミのモデルでの以前の研究では,TNFアンタゴニストが嗅覚機能を改善することを示唆しています.
- 嗅覚機能障害は,生活の質に大きな影響を与えます.
研究 の 目的:
- TNFアンタゴニストがヒトの嗅覚機能に及ぼす影響を調査する.
- 嗅覚障害を持つ患者で潜在的なランダム化比較試験のための予備データを収集する.
主な方法:
- TNFアンタゴニスト療法 (アダリムマブバイオシミラー) を開始する成人の患者を含む将来性のある単一センターコホート研究.
- 嗅覚機能は,拡張されたスニッフィン・スティック・テストを使用して,ベースラインおよび3ヶ月後に評価されました.
- 患者はまた,症状に関するアンケートも記入した.
主要な成果:
- 3ヶ月のTNFアンタゴニスト治療 (p=0.08) の後,全体的なTDIスコアの有意な改善は見られなかった.
- しかし,ベースラインの嗅覚機能障害 (n=20) の患者では,TDIスコアが統計的に有意に改善した (p=0.012).
結論:
- TNFアンタゴニストは,既存の嗅覚障害を有する患者の嗅覚機能を改善する可能性があることを示しています.
- 対象となる患者グループでのさらなる調査は,これらの発見を確認し,治療の可能性を探求するために正当化されています.
関連する概念動画
Olfaction
48.9K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
48.9K
Necrosis
6.7K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.7K
Cholinergic Antagonists: Pharmacokinetics
990
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
990
Cholinergic Antagonists: Therapeutic Uses
1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Transcription Factors
82.9K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.9K
Cholinergic Antagonists: Pharmacological Actions
1.8K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.8K

